This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
Clinical trial NCT05935085 · TERMINATED
Trial details
- NCT number
- NCT05935085
- Sponsor
- AnaptysBio, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-13
- Primary completion
- 2024-10-16
- Enrollment
- 201
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.